Pfizer Raises Profit Outlook Despite Mixed Q3 Results and Market Challenges

Pfizer exceeded earnings estimates and raised its full-year profit guidance despite a decline in sales, driven by cost-cutting measures and a one-time charge related to a Chinese biotech licensing deal. The company also announced a significant investment in U.S. manufacturing and is involved in a bidding war for the biotech Metsera, amidst ongoing negotiations with the Trump administration over drug pricing and tariffs.